Misuse and abuse of opioids has become a serious public health concern, leading to the FDA approving a risk evaluation and mitigation strategy (REMS) for opioids. REMS introduced new safety measures; however, there are still gaps in knowledge among health care professionals (HCPs) regarding acute and chronic pain pathways and the underlying mechanisms to clinical assessment and appropriate management of pain.
This CME Outfitters live and on demand webcast will focus on the FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain as well as the U.S. Department of Health and Human Services’ Pain Management Best Practices Inter-Agency Task Force Report Updates, Gaps, Inconsistencies, and Recommendations. Expert faculty will discuss the underlying mechanisms of acute and chronic pain pathways and how to utilize this knowledge to implement appropriate pain management strategies and educate patients about their pain, thus optimizing safe and effective, multimodal treatment plans.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
This activity is supported by an independent educational grant from Opioid Analgesic REMS Program Companies. Please visit OpioidAnalgesicREMS.com for additional programs. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).
Physicians, dentists, PAs, NPs, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Stanos reports that he is a consultant for Pfizer Inc.; Salix Pharmaceuticals; Sanofi; and SCILEX Pharmaceuticals, Inc.
Dr. Gebke has no disclosures to report.
Dr. Skolnik has no disclosures to report.
Dr. Helfand (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-011-H01-P.
Call us at 877.CME.PROS (877.263.7767).